Skip to content
2000
Volume 32, Issue 38
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Nodal nevus (NN) and melanoma metastasis (MM) have distinct biological and prognostic significance. They are characterized by different cytomorphological features and varying intranodal localization. However, in some cases, distinguishing them in standard hematoxylin and eosin-stained specimens can be challenging. The aim of this review is to evaluate the usefulness of markers in the diagnosis of NN and MM. The expression of selected markers in NN and MM was examined immunohistochemically in 27 studies. The frequency of HMB-45 and PRAME staining was significantly higher, while p16 was lower in MM than in NN. A slight increase of Ki-67 and decrease of 5-hmC expression in MM compared to NN were also observed. Meanwhile, staining of Melan-A/Mart-1, S-100, and SOX-10 was similar in NN and MM. However, none of the markers applied was completely specific for melanocytes. Although PRAME proved to have the strongest diagnostic potential, it was also detectable in other cell types, especially in lymphocytes and some breast cancers. Immunohistochemical staining of PRAME, HMB-45, and p16 may aid the diagnosis of NN and MM. Ki-67 and 5-hmC may also be of promising significance, whereas the expression of Melan-A/Mart-1, S-100, and SOX-10 does not allow distinguishing NN from MM.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673358592250408170859
2025-06-10
2025-11-01

  • From This Site

    /content/journals/cmc/10.2174/0109298673358592250408170859
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SahinT.K. RizzoA. AksoyS. GuvenD.C. Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: A systematic review and meta-analysis.Cancers20241610183510.3390/cancers1610183538791914
     [Google Scholar]
  2. GarbeC. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.Eur. J. Cancer202521511515210.1016/j.ejca.2024.11515239700658
     [Google Scholar]
  3. TasF. ErturkK. The course of stage III melanoma in accordance with the severity of node involvement.Curr. Med. Res. Opin.201935101819182410.1080/03007995.2019.162856331169423
     [Google Scholar]
  4. TasF. ErturkK. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.Int. J. Clin. Oncol.201924672172610.1007/s10147‑019‑01410‑430788673
     [Google Scholar]
  5. DumitraT. FariesM.B. Melanoma sentinel lymph node biopsy in the modern era.Surg. Oncol.20245710216210.1016/j.suronc.2024.10216239556928
     [Google Scholar]
  6. GershenwaldJ.E. ScolyerR.A. HessK.R. SondakV.K. LongG.V. RossM.I. LazarA.J. FariesM.B. KirkwoodJ.M. McArthurG.A. HayduL.E. EggermontA.M.M. FlahertyK.T. BalchC.M. ThompsonJ.F. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA Cancer J. Clin.201767647249210.3322/caac.2140929028110
     [Google Scholar]
  7. GarbeC. AmaralT. PerisK. HauschildA. ArenbergerP. Basset-SeguinN. BastholtL. BatailleV. BrochezL. del MarmolV. DrénoB. EggermontA.M.M. FargnoliM.C. ForseaA.M. HöllerC. KaufmannR. Kelleners-SmeetsN. LallasA. LebbéC. LeiterU. LongoC. MalvehyJ. Moreno-RamirezD. NathanP. PellacaniG. SaiagP. StockflethE. StratigosA.J. Van AkkooiA.C.J. VieiraR. ZalaudekI. LoriganP. MandalaM. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024.Eur. J. Cancer202521511515310.1016/j.ejca.2024.11515339709737
     [Google Scholar]
  8. HugdahlE. AzizS. KlingenT.A. AkslenL.A. Prognostic value of immune biomarkers in melanoma loco-regional metastases.PLoS One2025201e031528410.1371/journal.pone.031528439883679
     [Google Scholar]
  9. RizzoA. Nivolumab plus ipilimumab in melanoma brain metastases.Lancet Oncol.2022232e5210.1016/S1470‑2045(22)00010‑935114121
     [Google Scholar]
  10. GuvenD.C. ErulE. KaygusuzY. AkagunduzB. KilickapS. De LucaR. RizzoA. Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data.Support. Care Cancer2023311162410.1007/s00520‑023‑08083‑w37819422
     [Google Scholar]
  11. RizzoA. SantoniM. MollicaV. LogulloF. RoselliniM. MarchettiA. FaloppiL. BattelliN. MassariF. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study.Expert Opin. Drug Metab. Toxicol.202117121455146610.1080/17425255.2021.202940535029519
     [Google Scholar]
  12. RizzoA. MollicaV. TateoV. TassinariE. MarchettiA. RoselliniM. De LucaR. SantoniM. MassariF. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: The MOUSEION-05 study.Cancer Immunol. Immunother.20237261381139410.1007/s00262‑023‑03366‑x36695827
     [Google Scholar]
  13. CarlsonJ.A. RossJ.S. SlominskiA. LinetteG. MysliborskiJ. HillJ. MihmM. Jr. Molecular diagnostics in melanoma.J. Am. Acad. Dermatol.200552574377510.1016/j.jaad.2004.08.03415858465
     [Google Scholar]
  14. BlahetaH.J. SotlarK. BreuningerH. BueltmannB. RassnerG. GarbeC. HornyH.P. Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma?Melanoma Res.2001111576310.1097/00008390‑200102000‑0000711254116
     [Google Scholar]
  15. BrennickJ.B. YanS. False-positive cells in sentinel lymph nodes.Semin. Diagn. Pathol.200825211611910.1053/j.semdp.2008.03.00118697715
     [Google Scholar]
  16. ZubovitsJ. BuzneyE. YuL. DuncanL.M. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.Hum. Pathol.200435221722310.1016/j.humpath.2003.09.01914991540
     [Google Scholar]
  17. HellerR. BeckerJ. WasselleJ. BaekeyP. CruseC.W. CoxC. KingB. WoodH. ReintgenD.S. Detection of occult lymph node metastases in malignant melanoma.Ann. Plast. Surg.1992281747710.1097/00000637‑199201000‑000191642412
     [Google Scholar]
  18. SatzgerI. VölkerB. MeierA. SchenckF. KappA. GutzmerR. Prognostic significance of isolated HMB45 or melan A positive cells in Melanoma sentinel lymph nodes.Am. J. Surg. Pathol.20073181175118010.1097/PAS.0b013e3180341ebc17667539
     [Google Scholar]
  19. JenningsC. KimJ. Identification of nodal metastases in melanoma using sox-10.Am. J. Dermatopathol.201133547448210.1097/DAD.0b013e318204289321552103
     [Google Scholar]
  20. JungbluthA.A. Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes.Semin. Diagn. Pathol.200825212012510.1053/j.semdp.2008.05.00218697716
     [Google Scholar]
  21. OrchardG.E. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.Histochem. J.200032847548110.1023/A:100419223235711095072
     [Google Scholar]
  22. RonchiA. Zito MarinoF. MoscarellaE. BrancaccioG. ArgenzianoG. TroianiT. NapolitanoS. FrancoR. CozzolinoI. PRAME immunocytochemistry for the diagnosis of melanoma metastases in cytological samples.Diagnostics202212364610.3390/diagnostics1203064635328198
     [Google Scholar]
  23. Szumera-CiećkiewiczA. BosisioF. TeteryczP. AntoranzA. DeloguF. KoljenovićS. van de WielB.A. BlokxW. van KempenL.C. RutkowskiP. Christopher van AkkooiA. CookM. MassiD. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment.Eur. J. Cancer202013717518210.1016/j.ejca.2020.06.03732781392
     [Google Scholar]
  24. VrotsosE. AlexisJ. Can SOX-10 or KBA.62 replace S100 protein in immunohistochemical evaluation of sentinel lymph nodes for metastatic melanoma?Appl. Immunohistochem. Mol. Morphol.2016241262910.1097/PAI.000000000000014625611246
     [Google Scholar]
  25. BiernackaA. LinosK.D. DeLongP.A. SuriawinataA.A. PadmanabhanV. LiuX. A case of S-100 negative melanoma: A diagnostic pitfall in the workup of a poorly differentiated metastatic tumor of unknown origin.Cytojournal2016132110.4103/1742‑6413.19091427729935
     [Google Scholar]
  26. RiddleN.D. BuiM.M. When melanoma is negative for S100: Diagnostic pitfalls.Arch. Pathol. Lab. Med.2012136323723910.5858/arpa.2011‑0405‑LE22372898
     [Google Scholar]
  27. MohamedA. GonzalezR.S. LawsonD. WangJ. CohenC. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.Appl. Immunohistochem. Mol. Morphol.201321650651010.1097/PAI.0b013e318279bc0a23197006
     [Google Scholar]
  28. GradeckiS.E. SlingluffC.L.Jr GruA.A. PRAME expression in 155 cases of metastatic melanoma.J. Cutan. Pathol.202148447948510.1111/cup.1387632939793
     [Google Scholar]
  29. LezcanoC. JungbluthA.A. NehalK.S. HollmannT.J. BusamK.J. PRAME expression in melanocytic tumors.Am. J. Surg. Pathol.201842111456146510.1097/PAS.000000000000113430045064
     [Google Scholar]
  30. OhsieS.J. SarantopoulosG.P. CochranA.J. BinderS.W. Immunohistochemical characteristics of melanoma.J. Cutan. Pathol.200835543344410.1111/j.1600‑0560.2007.00891.x18399807
     [Google Scholar]
  31. PiaoY. GuoM. GongY. Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens.Cancer200811429410110.1002/cncr.2334518260089
     [Google Scholar]
  32. ChangO. ArgenyiZ. Loss of conventional melanocytic markers in malignant melanoma and lymph node metastasis; an uncommon but dangerous pitfall.Am. J. Dermatopathol.2017391076076310.1097/DAD.000000000000073727759690
     [Google Scholar]
  33. GaoZ. StanekA. ChenS. A metastatic melanoma with an unusual immunophenotypic profile.Am. J. Dermatopathol.200729216917110.1097/DAD.0b013e31802e49a317414440
     [Google Scholar]
  34. SteppertC. KrugmannJ. SterlacciW. Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis.Pathol. Oncol. Res.20202631777177910.1007/s12253‑019‑00761‑731654227
     [Google Scholar]
  35. BiddleD.A. EvansH.L. KempB.L. El-NaggarA.K. HarvellJ.D. WhiteW.L. IskandarS.S. PrietoV.G. Intraparenchymal nevus cell aggregates in lymph nodes: A possible diagnostic pitfall with malignant melanoma and carcinoma.Am. J. Surg. Pathol.200327567368110.1097/00000478‑200305000‑0001112717252
     [Google Scholar]
  36. El SharouniM.A. LaeijendeckerA.E. SuijkerbuijkK.P.M. WitkampA.J. SigurdssonV. van DiestP.J. van GilsC.H. BlokxW.A.M. High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment.Eur. J. Cancer202114910511310.1016/j.ejca.2021.03.00133848712
     [Google Scholar]
  37. HoltJ.B. SanguezaO.P. LevineE.A. ShenP. BergmanS. GeisingerK.R. CreagerA.J. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.Am. J. Clin. Pathol.20041211586310.1309/Y5QAD623MYA21PUY14750241
     [Google Scholar]
  38. KarimipourD.J. LoweL. SuL. HamiltonT. SondakV. JohnsonT.M. FullenD. Standard immunostains for melanoma in sentinel lymph node specimens: Which ones are most useful?J. Am. Acad. Dermatol.200450575976410.1016/j.jaad.2003.07.01615097961
     [Google Scholar]
  39. LezcanoC. PulitzerM. MoyA.P. HollmannT.J. JungbluthA.A. BusamK.J. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma.Am. J. Surg. Pathol.202044450350810.1097/PAS.000000000000139331633488
     [Google Scholar]
  40. SaabJ. Santos-ZabalaM.L. LodaM. StackE.C. HollmannT.J. Fatty acid synthase and Acetyl-CoA carboxylase are expressed in nodal metastatic melanoma but not in benign intracapsular nodal nevi.Am. J. Dermatopathol.201840425926410.1097/DAD.000000000000093928654463
     [Google Scholar]
  41. AzzopardiJ.G. RossC.M.D. FrizzeraG. Blue naevi of lymph node capsule.Histopathology19771645146110.1111/j.1365‑2559.1977.tb01684.x615846
     [Google Scholar]
  42. EpsteinJ.I. ErlandsonR.A. RosenP.P. Nodal blue nevi.Am. J. Surg. Pathol.198481290791510.1097/00000478‑198412000‑000036097130
     [Google Scholar]
  43. GoldmanR.L. Blue naevus of lymph node capsule: Report of a unique case.Histopathology19815444545010.1111/j.1365‑2559.1981.tb01805.x7275022
     [Google Scholar]
  44. LamovecJ. Blue nevus of the lymph node capsule. Report of a new case with review of the literature.Am. J. Clin. Pathol.198481336737210.1093/ajcp/81.3.3676322570
     [Google Scholar]
  45. MasciP. CiardiA. Di TondoU. Blue nevus of the lymph node capsule.J. Dermatol. Surg. Oncol.198410859659810.1111/j.1524‑4725.1984.tb01259.x6747071
     [Google Scholar]
  46. KimH.J. SeoJ.W. RohM.S. LeeJ.H. SongK.H. Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen.J. Am. Acad. Dermatol.201879470671310.1016/j.jaad.2018.04.01629673774
     [Google Scholar]
  47. OgawaK. KobayashiN. MiyagawaF. NakaiT. FukumotoT. MitsuiY. AraiE. AsadaH. Case of nodal nevus with melanocytic cell aggregates in the lymphatic hilum: A potential diagnostic pitfall that requires differentiation from metastatic melanoma of the lymph node.J. Dermatol.2020476e242e24410.1111/1346‑8138.1532532201978
     [Google Scholar]
  48. LeeJ.J. GranterS.R. LagaA.C. SaavedraA.P. ZhanQ. GuoW. XuS. MurphyG.F. LianC.G. 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies.Mod. Pathol.201528221822910.1038/modpathol.2014.9925081754
     [Google Scholar]
  49. DandekarM. LoweL. FullenD.R. JohnsonT.M. SabelM.S. WongS.L. PatelR.M. Discordance in histopathologic evaluation of melanoma sentinel lymph node biopsy with clinical follow-up: Results from a prospectively collected database.Ann. Surg. Oncol.201421113406341110.1245/s10434‑014‑3773‑824845727
     [Google Scholar]
  50. BautistaN.C. CohenS. AndersK.H. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review.Am. J. Clin. Pathol.1994102110210810.1093/ajcp/102.1.1028037154
     [Google Scholar]
  51. de BeerF.S.A. van DiestP.J. SigurdssonV. El SharouniM. Intra-nodal nevi in sentinel node-negative patients with cutaneous melanoma does not influence survival.J. Eur. Acad. Dermatol. Venereol.201933122291229510.1111/jdv.1581431318994
     [Google Scholar]
  52. DohseL. FerringerT. Nodal blue nevus: a pitfall in lymph node biopsies.J. Cutan. Pathol.201037110210410.1111/j.1600‑0560.2009.01304.x19615001
     [Google Scholar]
  53. FisherC.J. HillS. MillisR.R. Benign lymph node inclusions mimicking metastatic carcinoma.J. Clin. Pathol.199447324524710.1136/jcp.47.3.2458163697
     [Google Scholar]
  54. GambichlerT. SchollL. StückerM. BecharaF.G. HoffmannK. AltmeyerP. OthlinghausN. Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes.Am. J. Clin. Pathol.2013139556657310.1309/AJCPG83CMAVFBWLC23596107
     [Google Scholar]
  55. KretschmerL. SchnabelV. KromerC. Bauer-BüntzelC. RichterA. BremmerF. KückF. JuliusK. MitteldorfC. SchönM.P. Melanocytic nevi in sentinel lymph nodes: Association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas.J. Cancer Res. Clin. Oncol.2022148113125313410.1007/s00432‑021‑03894‑y35059868
     [Google Scholar]
  56. McCarthyS.W. PalmerA.A. BaleP.M. HirstE. Naevus cells in lymph nodes.Pathology19746435135810.3109/003130274090773464449672
     [Google Scholar]
  57. RicciC. DikaE. LambertiniM. AmbrosiF. ChiarucciF. ChillottiS. FiorentinoM. FabbriE. TassoneD. VeronesiG. TartariF. CortiB. The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma.Pathol. Res. Pract.202223315380510.1016/j.prp.2022.15380535361504
     [Google Scholar]
  58. RidolfiR.L. RosenP.P. ThalerH. Nevus cell aggregates associated with lymph nodes: Estimated frequency and clinical significance.Cancer197739116417110.1002/1097‑0142(197701)39:1<164::AID‑CNCR2820390127>3.0.CO;2‑T832230
     [Google Scholar]
  59. SmithO.J. CoelhoJ.A.J. TrevattA.E. RossG.L. Clinical significance of intra-nodal naevi in sentinel node biopsies for malignant melanoma.Eur. J. Surg. Oncol.20164291427143110.1016/j.ejso.2016.04.05727262872
     [Google Scholar]
  60. SubramonyC. LewinJ.R. MedM. Nevus cells within lymph nodes. Possible metastases from a benign intradermal nevus.Am. J. Clin. Pathol.198584222022310.1093/ajcp/84.2.2204025228
     [Google Scholar]
  61. LohmannC.M. IversenK. JungbluthA.A. BerwickM. BusamK.J. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma.Am. J. Surg. Pathol.200226101351135710.1097/00000478‑200210000‑0001212360050
     [Google Scholar]
  62. SeeS.H.C. FinkelmanB.S. YeldandiA.V. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.Pathol. Res. Pract.2020216915310510.1016/j.prp.2020.15310532825968
     [Google Scholar]
  63. HrubanR.H. EckertF. BaričevićB. Melanocytes of a melanocytic nevus in a lymph node from a patient with a primary cutaneous melanoma associated with a small congenital nevus.Am. J. Dermatopathol.199012440240710.1097/00000372‑199008000‑000122203272
     [Google Scholar]
  64. BichelP. ØrnsholtJ. Benign nevus cells in the lymph nodes.Acta Pathol. Microbiol. Scand. Suppl.1988961-611712210.1111/j.1699‑0463.1988.tb05277.x3345256
     [Google Scholar]
  65. BowenA.R. DuffyK.L. ClaytonF.C. AndtbackaR.H.I. FlorellS.R. Benign melanocytic lymph node deposits in the setting of giant congenital melanocytic nevi: The large congenital nodal nevus.J. Cutan. Pathol.2015421183283910.1111/cup.1258026268779
     [Google Scholar]
  66. DavisJ. PatilJ. AydinN. MishraA. MisraS. Capsular nevus versus metastatic malignant melanoma – A diagnostic dilemma.Int. J. Surg. Case Rep.201629202410.1016/j.ijscr.2016.10.04027810606
     [Google Scholar]
  67. Gonzàlez-FarréM. RonenS. KeiserE. PrietoV.G. AungP.P. Three types of nodal melanocytic nevi in sentinel lymph nodes of patients with melanoma: Pitfalls, immunohistochemistry, and a review of the literature.Am. J. Dermatopathol.2020421073974410.1097/DAD.000000000000164532271206
     [Google Scholar]
  68. HuJ. RenM. CaiX. ZhangY. LvJ.J. KongY.Y. Nevus cell aggregates massively occupying parenchyma of an external iliac lymph node: A case report and review of the literature.J. Cutan. Pathol.202047121175118010.1111/cup.1380532644206
     [Google Scholar]
  69. KannerW.A. BarryC.I. SmartC.N. FrishbergD.P. BinderS.W. WickM.R. Reticulin and NM23 staining in the interpretation of lymph nodal nevus rests.Am. J. Dermatopathol.201335445245710.1097/DAD.0b013e318272c10423694823
     [Google Scholar]
  70. NonakaD. ChiribogaL. RubinB.P. Sox10: A pan-schwannian and melanocytic marker.Am. J. Surg. Pathol.20083291291129810.1097/PAS.0b013e3181658c1418636017
     [Google Scholar]
  71. PianaS. TagliaviniE. RagazziM. ZanelliM. ZalaudekI. CiarrocchiA. ValliR. Lymph node melanocytic nevi: Pathogenesis and differential diagnoses, with special reference to p16 reactivity.Pathol. Res. Pract.2015211538138810.1016/j.prp.2015.01.00325661066
     [Google Scholar]
  72. YanS. BrennickJ.B. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes.Am. J. Surg. Pathol.200428559660010.1097/00000478‑200405000‑0000515105646
     [Google Scholar]
  73. ZenginH.B. YildizB. PukhalskayaT. SmollerB.R. FLI -1/ Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.J. Cutan. Pathol.202350324725810.1111/cup.1437336454046
     [Google Scholar]
  74. GambichlerT. SandM. SkryganM. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma.Melanoma Res.201323321822010.1097/CMR.0b013e32835f9bd423458759
     [Google Scholar]
  75. KatarzynaL. KyriakosO. LindaV. IngridS. PetraW. KarinÖ. Evaluation of tubulin β-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma.Ann. Diagn. Pathol.20247215233210.1016/j.anndiagpath.2024.15233238776734
     [Google Scholar]
  76. RawsonR.V. ShteinmanE.R. AnsarS. VergaraI.A. ThompsonJ.F. LongG.V. ScolyerR.A. WilmottJ.S. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.Pathology202254786387310.1016/j.pathol.2022.05.01235987723
     [Google Scholar]
  77. UchiyamaR. UharaH. UchiyamaA. OgawaE. TakazawaY. AshidaA. KogaH. HayashiK. KiniwaY. OkuyamaR. 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi.J. Dermatol. Sci.201473216116310.1016/j.jdermsci.2013.09.00824169492
     [Google Scholar]
  78. KuźbickiŁ. BrożynaA.A. The markers auxiliary in differential diagnosis of early melanomas and benign nevi sharing some similar features potentially leading to misdiagnosis – A review of immunohistochemical studies.Cancer Invest.2022401085286710.1080/07357907.2022.213441536214582
     [Google Scholar]
  79. BahmadH.F. OhK.S. AlexisJ. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.J. Cutan. Pathol.202350876377210.1111/cup.1443837114299
     [Google Scholar]
  80. KohS.S. CassarinoD.S. Immunohistochemical expression of p16 in melanocytic lesions: An updated review and meta-analysis.Arch. Pathol. Lab. Med.2018142781582810.5858/arpa.2017‑0435‑RA29939777
     [Google Scholar]
  81. SankiA. LiW. ColmanM. KarimR.Z. ThompsonJ.F. ScolyerR.A. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.Pathology200739655155710.1080/0031302070168440918027257
     [Google Scholar]
  82. BeleauaM.A. JungI. BraicuC. MilutinD. GurzuS. SOX11, SOX10 and MITF gene interaction: A possible diagnostic tool in malignant melanoma.Life202111428110.3390/life1104028133801642
     [Google Scholar]
  83. FerringerT. Update on immunohistochemistry in melanocytic lesions.Dermatol. Clin.2012304567579, v10.1016/j.det.2012.06.00723021046
     [Google Scholar]
  84. IvanD. PrietoV.G. Use of immunohistochemistry in the diagnosis of melanocytic lesions: Applications and pitfalls.Future Oncol.2010671163117510.2217/fon.10.8120624128
     [Google Scholar]
  85. WickM.R. SwansonP.E. RocamoraA. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors.J. Cutan. Pathol.198815420120710.1111/j.1600‑0560.1988.tb00544.x3053811
     [Google Scholar]
  86. OroszZ. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours.Histopathology199934651752510.1111/j.1365‑2559.1999.00679.x10383696
     [Google Scholar]
  87. PrietoV.G. SheaC.R. Use of immunohistochemistry in melanocytic lesions.J. Cutan. Pathol.200835s2Suppl. 211010.1111/j.1600‑0560.2008.01130.x18976412
     [Google Scholar]
  88. PrietoV.G. SheaC.R. Immunohistochemistry of melanocytic proliferations.Arch. Pathol. Lab. Med.2011135785385910.5858/2009‑0717‑RAR.121732774
     [Google Scholar]
  89. ChanM.P. ChanM.M. TahanS.R. Melanocytic nevi in pregnancy: Histologic features and Ki-67 proliferation index.J. Cutan. Pathol.201037884385110.1111/j.1600‑0560.2009.01491.x20015190
     [Google Scholar]
  90. NasrM.R. El-ZammarO. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.Am. J. Dermatopathol.200830211712210.1097/DAD.0b013e318162405418360113
     [Google Scholar]
  91. VyasN.S. CharifaA. DesmanG.T. GoldbergM. SinghR. PhelpsR.G. McNiffJ.M. Observational study examining the diagnostic practice of Ki67 staining for melanocytic lesions.Am. J. Dermatopathol.201941748849110.1097/DAD.000000000000137931233404
     [Google Scholar]
  92. FullenD.R. ReedJ.A. FinnertyB. McNuttN.S. S100A6 preferentially labels type C nevus cells and nevic corpuscles: Additional support for Schwannian differentiation of intradermal nevi.J. Cutan. Pathol.200128839339910.1034/j.1600‑0560.2001.028008393.x11493376
     [Google Scholar]
  93. PytlakB. Prochorec-SobieszekM. Szumera- CiećkiewiczA. SOX10 as an immunohistochemical marker in cancer diagnostics. Nowotwory. J. Oncol.20196925864
     [Google Scholar]
  94. GrilliniM. RicciC. PinoV. PedriniS. FiorentinoM. CortiB. HMB45/PRAME, a novel double staining for the diagnosis of melanocytic neoplasms: Technical aspects, results, and comparison with other commercially available staining (PRAME and Melan A/PRAME).Appl. Immunohistochem. Mol. Morphol.2022301141810.1097/PAI.000000000000097234508017
     [Google Scholar]
  95. SirefA.B. HuynhC.A.T. BalzerB.L. FrishbergD.P. EssnerR. ShonW. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.J. Cutan. Pathol.201946426126610.1111/cup.1341230632191
     [Google Scholar]
  96. Colon CartagenaL. WangG.Y. IdowuM.O. SmithS.C. MochelM.C. SOX10-positive perivascular cells in sentinel lymph nodes: A reliably intrinsic internal control.J. Cutan. Pathol.202047441541710.1111/cup.1364331894865
     [Google Scholar]
  97. WillisB.C. JohnsonG. WangJ. CohenC. SOX10: A useful marker for identifying metastatic melanoma in sentinel lymph nodes.Appl. Immunohistochem. Mol. Morphol.201523210911210.1097/PAI.000000000000009725356946
     [Google Scholar]
  98. BlochinE. NonakaD. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes.Histopathology200955562662810.1111/j.1365‑2559.2009.03415.x19912373
     [Google Scholar]
  99. KahnH.J. MarksA. ThomH. BaumalR. Role of antibody to S100 protein in diagnostic pathology.Am. J. Clin. Pathol.198379334134710.1093/ajcp/79.3.3416299096
     [Google Scholar]
  100. Merelo AlcocerV. FlammA. ChenG. HelmK. SOX10 Immunostaining in granulomatous dermatoses and benign reactive lymph nodes.J. Cutan. Pathol.201946858659010.1111/cup.1347030957251
     [Google Scholar]
  101. TrinidadC.M. Torres-CabalaC.A. CurryJ.L. PrietoV.G. AungP.P. Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters.J Clin Pathol201972426527010.1136/jclinpath‑2018‑20541730275100
     [Google Scholar]
  102. MahmoodM.N. LeeM.W. LindenM.D. NathansonS.D. HornyakT.J. ZarboR.J. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells.Mod. Pathol.200215121288129310.1097/01.MP.0000037313.33138.DF12481009
     [Google Scholar]
  103. DwarakanathS. LeeA.K.C. DelellisR.A. SilvermanM.L. FrascaL. WolfeH.J. S-100 protein positivity in breast carcinomas: A potential pitfall in diagnostic immunohistochemistry.Hum. Pathol.198718111144114810.1016/S0046‑8177(87)80382‑92824323
     [Google Scholar]
  104. MiettinenM. McCueP.A. Sarlomo-RikalaM. BiernatW. CzapiewskiP. KopczynskiJ. ThompsonL.D. LasotaJ. WangZ. FetschJ.F. Sox10-a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: A systematic analysis of 5134 tumors.Am. J. Surg. Pathol.201539682683510.1097/PAS.000000000000039825724000
     [Google Scholar]
  105. BonettiF. ColombariR. ManfrinE. ZamboniG. MartignoniG. MombelloA. ChilosiM. Breast carcinoma with positive results for melanoma marker (HMB-45). HMB-45 immunoreactivity in normal and neoplastic breast.Am. J. Clin. Pathol.198992449149510.1093/ajcp/92.4.4912552794
     [Google Scholar]
  106. BusamK.J. JungbluthA.A. Melan-A, a new melanocytic differentiation marker.Adv. Anat. Pathol.199961121810.1097/00125480‑199901000‑0000210197235
     [Google Scholar]
  107. Cimino-MathewsA. Novel uses of immunohistochemistry in breast pathology: Interpretation and pitfalls.Mod. Pathol.202134Suppl. 1627710.1038/s41379‑020‑00697‑333110239
     [Google Scholar]
  108. NewmanJ. BrahmbhattM. StoffB.K. MartinezA.P. S-100 protein and SOX10 -positive breast carcinoma mimicking metastatic melanoma.J. Cutan. Pathol.202047121187119110.1111/cup.1382232710508
     [Google Scholar]
  109. KriegsmannK. FlechtenmacherC. HeilJ. KriegsmannJ. MechtersheimerG. AulmannS. WeichertW. SinnH.P. KriegsmannM. Immunohistological expression of SOX-10 in triple-negative breast cancer: A descriptive analysis of 113 samples.Int. J. Mol. Sci.20202117640710.3390/ijms2117640732899175
     [Google Scholar]
  110. FliorentR. BenedettoC. TherouxZ. Metastatic triple-negative breast carcinoma mimicking melanoma: A potential diagnostic pitfall.J. Cutan. Pathol.202451965465710.1111/cup.1465838767140
     [Google Scholar]
  111. CuriglianoG. BagnardiV. GhioniM. LouahedJ. BrichardV. LehmannF.F. MarraA. TrapaniD. CriscitielloC. VialeG. Expression of tumor-associated antigens in breast cancer subtypes.Breast20204920220910.1016/j.breast.2019.12.00231869767
     [Google Scholar]
  112. TessariA. PillaL. SilviaD. DucaM. PaoliniB. CarcangiuM.L. MarianiL. de BraudF.G. CrestaS. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?Breast201842687310.1016/j.breast.2018.08.10630189381
     [Google Scholar]
  113. GradeckiS.E. Valdes-RodriguezR. WickM.R. GruA.A. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna.Histopathology20217871000100810.1111/his.1431233280156
     [Google Scholar]
  114. YatesA.J. BanerjeeS.S. BishopP.W. GrahamK.E. HMB-45 in non-melanocytic tumours.Histopathology199323547747810.1111/j.1365‑2559.1993.tb00499.x8314224
     [Google Scholar]
  115. YaoD.X. SoslowR.A. HedvatC.V. LeitaoM. BaergenR.N. Melan-A (A103) and inhibin expression in ovarian neoplasms.Appl. Immunohistochem. Mol. Morphol.200311324424910.1097/00129039‑200309000‑0000712966351
     [Google Scholar]
  116. ZuoL. YouH. CaiZ. LiaoS. LuX. LiL. HuangW. Melan-A expression in non-melanocytic carcinoma: A potential diagnostic pitfall.Histol. Histopathol.20233981037104110.14670/HH‑18‑69638205829
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673358592250408170859
Loading
The Markers Auxiliary in Distinguishing between Nodal Nevi and Melanoma Metastases
Curr. Med. Chem. 32, 8580 (2025); https://doi.org/10.2174/0109298673358592250408170859
/content/journals/cmc/10.2174/0109298673358592250408170859
/content/journals/cmc/10.2174/0109298673358592250408170859
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): diagnosis; eosin staining; hematoxylin; immunohistochemistry; marker; melanoma metastasis; Nodal nevus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test